tiprankstipranks

Aridis drops after endpoint in AR-301–002 study not statistically significant

Shares of Aridis Pharmaceuticals are dropping over 40% in late trading on Wednesday evening, to 71c per share, after closing the regular session up 46.4% to $1.23 per share, after reporting that the sample size of the study was limited and "lacked of statistical significance in the primary endpoint."

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ARDS:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue